ArticleActa pharmaceutica Sinica. B2022

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.